Insights

Process simulation allows engineering teams to evaluate whether process requirements, equipment concepts, utilities and operating strategies will work together before expensive design and procurement decisions are finalised. As Indian biopharmaceutical manufacturers move beyond traditional vaccine

India’s biopharma manufacturing capabilities have long been recognised globally, particularly in generics and vaccines. But the opportunity ahead is broader. As Indian companies move into complex biologics, biosimilars, advanced therapies and global contract manufacturing, the

India’s biopharma sector is scaling fast. Vaccine manufacturing, biosimilars, and plasma-derived therapies are moving from pilot to commercial volumes, and facilities built for yesterday’s product mix are being asked to do far more than they

A pharmaceutical process that performs flawlessly in the laboratory does not automatically perform the same way in commercial production.  This reality sits at the heart of every scale-up project. Across the pharmaceutical industry, companies invest

India’s Union Budget 2026 and the national biopharma initiatives are accelerating investment across advanced therapeutics, vaccines, and biologics manufacturing. Programs such as the government’s Biopharma Mission, aimed at strengthening translational research and domestic manufacturing capabilities,

India’s biopharmaceutical industry is entering a new phase of expansion. Beyond its established leadership in vaccines and biosimilars, the country is now investing across advanced modalities, including monoclonal antibodies, cell and gene therapies, plasma products,

India’s pharmaceutical manufacturing sector is experiencing rapid growth, reinforcing its position as the “pharmacy of the world.” According to the EY-Parthenon–OPPI report, pharma exports reached $27.85 billion in FY 2023–24, nearing the $30 billion mark.

The global fermenters market reached $1.80 billion in 2025 and is projected to reach $2.63 billion by 2032 at a 5.60% CAGR, driven by rising biopharma demand for vaccines, biosimilars, and recombinant proteins. In the

In the highly regulated and complex pharma and biotech sectors, fragmented engineering processes often lead to costly delays, compliance issues, and inefficient facilities that hinder production scale-up. Project managers, production heads, and CEOs need a

After the founders closed their seed round for a biotech startup, it felt like the hardest part was behind them. The upstream platform for a new class of recombinant proteins had worked beautifully in the

Fermentation is the backbone of contemporary biopharmaceutical production, enabling manufacturers to create a wide range of products, from life-saving vaccines to high-value APIs and recombinant proteins. For production and project managers, mastering the principles of

For procurement heads and project managers in the pharmaceutical industry, few choices are as consequential as selecting the right mixer or agitator supplier. At the heart of every bioreactor and process vessel, the agitator must